GS Group and Goldman Sachs & Co. LLC disclose joint NVRO holding of 1,172 shares
Rhea-AI Filing Summary
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly reported beneficial ownership of 1,172 shares of Nevro Corp. common stock, representing 0.0% of the class. The filing shows shared voting power of 905 shares and shared dispositive power of 1,172 shares, with no sole voting or dispositive power recorded.
The Schedule 13G/A states these holdings are reported as held in the ordinary course of business and not for the purpose of influencing control. The filing also discloses that Goldman Sachs & Co. LLC is a subsidiary of The Goldman Sachs Group, Inc., and the parties executed a joint filing agreement documenting the joint submission.
Positive
- Clear joint filing and parent-subsidiary disclosure clarifying the relationship between the reporting entities
- Holdings reported as held in the ordinary course of business, not for control, reducing governance concerns
Negative
- None.
Insights
Small, non-controlling position; routine disclosure with negligible market impact.
The filing quantifies a very small stake of 1,172 shares in NVRO, equal to 0.0% of the outstanding class, with 0 shares held with sole voting or dispositive power and 905 shares reported as shared voting power. This scale of ownership is immaterial to company control or earnings expectations and is consistent with brokerage or advisory activities. The explicit statement that the shares are held in the ordinary course and not to influence control reduces regulatory and governance concerns for investors.
Disclosure shows appropriate joint filing and parent-subsidiary attribution; no governance action implied.
The Schedule 13G/A includes a joint filing agreement and an exhibit clarifying that Goldman Sachs & Co. LLC is a subsidiary of The Goldman Sachs Group, Inc. Itemized voting and dispositive powers show shared, not sole, authority, and the statement in the filing certifies the holdings are not intended to change or influence control. For governance review, this is a compliant, routine disclosure without material impact on board composition or control risks.